Evidence map›Paper›PMID 29426483›Full record

ArticleVeterinary parasitology2018

In vitro growth inhibition of Theileria equi by bumped kinase inhibitors.

Fernanda Gimenez, Siddra A Hines, Ryan Evanoff, Kayode K Ojo, Wesley C Van Voorhis, Dustin J Maly, Rama S R Vidadala, Robert H Mealey

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary parasitology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Tulathromycin and Diclazuril Lack Efficacy againstPathogens (Basel, Switzerland) · 2023
    Article
  2. Imidocarb Dipropionate Lacks Efficacy againstPathogens (Basel, Switzerland) · 2020
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fernanda GimenezDepartment of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, 99164, USA. Electronic address: fgimenez@vetmed.wsu.edu.
Siddra A HinesVeterinary Research and Development, Inc., Pullman, WA, 99163, USA.
Ryan EvanoffDepartment of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, 99164, USA.
Kayode K OjoDepartment of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, WA, 98109, USA.
Wesley C Van VoorhisDepartment of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, WA, 98109, USA; Department of Global Health, University of Washington, Seattle, WA, 98195, USA.
Dustin J MalyDepartment of Chemistry, University of Washington, Seattle, WA, 98195, USA; Department of Biochemistry, University of Washington, Seattle, WA, 98195, USA.
Rama S R VidadalaDepartment of Chemistry, University of Washington, Seattle, WA, 98195, USA.
Robert H MealeyDepartment of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, 99164, USA.
University of Washington · USWashington State University · US

Funding

Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&ToxoplasmosisR01AI111341 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$6.4M
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvumR01AI089441 · NIAID · UNIVERSITY OF WASHINGTON · PI MERRITT, ETHAN A, PARSONS, MARILYN · 2010 to 2014
$5.0M
Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and NeosporosisR01HD080670 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$1.9M
NIAID NIH HHS R01 AI089441NIAID NIH HHS R01 AI111341NICHD NIH HHS R01 HD080670
6 · The paper itself

Abstract

introductionTheileria equi, an etiologic agent of equine piroplasmosis, is a tick-transmitted hemoprotozoan of the phylum Apicomplexa. Recent outbreaks of piroplasmosis in the United States have renewed interest in safe and effective treatment options. Although imidocarb dipropionate (IMD) is the drug of choice for clearance of T. equi, adverse reactions and recently documented resistance support the need for alternative therapeutic strategies. The recently described bumped kinase inhibitors (BKIs) are a new class of compounds that could potentially be used as safe and effective alternatives to IMD. In an initial effort to evaluate this potential, herein we determined the T. equi growth inhibitory activity of 11 BKIs relative to that of IMD and the previously tested BKI 1294. Because some BKIs have known human ether-à-go-go related gene (hERG) channel activity, we also assessed the hERG activity of each compound with the goal to identify those with the highest potency against T. equi coupled with the lowest potential for cardiotoxicity.

resultsSix BKIs inhibited T. equi growth in vitro, including the previously evaluated BKI 1294 which was used as a positive control. All six compounds were significantly less potent (higher 50% effective concentration (EC

conclusionsThe BKI compounds evaluated in this study inhibited T. equi in vitro and had diverse hERG activity. Based on these considerations, three compounds would be suitable for further evaluation. While these results provide a foundation for future work, in vivo pharmacokinetic, pharmacodynamics, and safety studies are needed before BKI compounds can be recommended for clinical use in T. equi infected horses.

Indexed as

AnimalsAntiprotozoal AgentsBabesiosisCattleHorse DiseasesHorsesHumansImidocarbProtein Kinase InhibitorsTheileriaTheileriasisAntiprotozoal AgentsImidocarbimidocarb dipropionateProtein Kinase InhibitorsApicomplexanBumped kinase inhibitorPiroplasmosisTheileria equi

Identifiers

PMID29426483
PMCPMC5959018
OpenAlexW2782459855

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.